BrainStorm Cell Therapeutics Company Profile (NASDAQ:BCLI)

Analyst Ratings

Consensus Ratings for BrainStorm Cell Therapeutics (NASDAQ:BCLI) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (108.33% upside)

Analysts' Ratings History for BrainStorm Cell Therapeutics (NASDAQ:BCLI)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016Maxim GroupReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for BrainStorm Cell Therapeutics (NASDAQ:BCLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/10/2016Q116($0.25)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/17/2015Q3($0.14)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.13)($0.12)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($0.14)($0.12)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2015Q414($0.18)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.12)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q3 14($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BrainStorm Cell Therapeutics (NASDAQ:BCLI)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.08)($0.08)($0.08)
Q2 20161($0.10)($0.10)($0.10)
Q3 20161($0.10)($0.10)($0.10)
Q4 20161($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BrainStorm Cell Therapeutics (NASDAQ:BCLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BrainStorm Cell Therapeutics (NASDAQ:BCLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/16/2015Robert G L ShorrDirectorSell10,800$2.71$29,268.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Malcolm S. TaubDirectorSell41,742$2.60$108,529.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Malcolm S. TaubDirectorSell13,480$2.73$36,800.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015International Holdings Ltd AccMajor ShareholderBuy2,000$2.58$5,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015International Holdings Ltd AccMajor ShareholderBuy9,200$2.34$21,528.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Yoram BibringCFOBuy8,500$3.04$25,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Yoram BibringCFOBuy41,500$2.92$121,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014International Holdings Ltd AccMajor ShareholderBuy8,600$4.06$34,916.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014International Holdings Ltd AccMajor ShareholderBuy6,700$4.14$27,738.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2014International Holdings Ltd AccMajor ShareholderBuy11,000$4.17$45,870.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Anthony S FiorinoCEOBuy18,000$0.28$5,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014International Holdings Ltd AccMajor ShareholderBuy130,000$0.29$37,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014International Holdings Ltd AccMajor ShareholderBuy150,000$0.35$52,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2014International Holdings Ltd AccMajor ShareholderBuy939,600$0.30$281,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for BrainStorm Cell Therapeutics (NASDAQ:BCLI)
DateHeadline
07/21/16 02:46 PMIncreased Stock Volatility Watch: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Engelwood Daily
07/21/16 02:46 PMShares Losing Ground in Trade: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - TGP
07/21/16 02:46 PMBrainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Price Volatility Hits An Extreme High - CML News
07/20/16 10:50 AMNew Market Research Report: BrainStorm Cell Therapeutics Inc. (BCLI) - Financial and Strategic SWOT Analysis Review
07/19/16 02:47 PMBrainstorm Cell Therapeutics (NASDAQ:BCLI) Announces NurOwn Phase 2 Met Primary Endpoint: Progenics ... - KC Register
07/19/16 02:47 PMShares Losing Ground in Session: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - TGP
07/19/16 08:57 AMBrainstorm's NurOwn cells better than placebo in ALS patients, but more complete data needed; shares up 5% premarket
07/19/16 08:57 AMWhat''s In Store For BCLI: A Smooth Sailing Or Perfect Storm?
07/18/16 02:50 PMInvestor Watch: Volatility Recap on Shares of: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Engelwood Daily
07/18/16 02:50 PMMost Volatile Healthcare Stocks- Synergy Pharmaceuticals (NASDAQ:SGYP), Brainstorm Cell Therapeutics (NASDAQ ... - Seneca Globe
07/18/16 02:50 PMStock Declining in Trading Session: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - TGP
07/18/16 02:50 PMBrainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) Is About To Release Clinical Study Results - Scibility Media
07/18/16 12:30 PMBCLI: Phase 2 ALS Trial Shows Clinical Benefit From NurOwn™ Treatment -
07/18/16 11:57 AMA Look at Five Stocks Trending on Monday -
07/18/16 07:45 AMWhat's In Store For BCLI: A Smooth Sailing Or Perfect Storm?
07/18/16 07:45 AMBrainstorm Cell Therapeutics (BCLI) Announces NurOwn Phase 2 Met Primary Endpoint in ALS
07/18/16 07:14 AMBrainstorm Cell Therapeutics' stock jumps after ALS drug trial results -
07/18/16 07:13 AMBRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements an -
07/18/16 07:01 AMBrainstorm: New ALS Stem Cell Results Support Start of Pivotal Clinical Trial -
07/18/16 07:00 AMBrainStorm Announces Positive Top Line Results from the U.S. Phase 2 Study of NurOwn® in Patients with Amyotrophic Lateral Sclerosis (ALS) - [PR Newswire] - HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 18, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced results from the recently completed U.S. randomized, double-blind, placebo-controlled phase 2 Study of NurOwn® in Patients with ALS. "I would like to thank the patients who participated in this clinical trial as well as the investigators, DSMB members and all those who contributed to the successful completion of this trial.
07/16/16 02:44 PMWatch Out For BCLI, RARE's Phase 3 Trial Hits Goal, JUNO Opens Wallet - RTT News
07/16/16 02:44 PMIncreased Volatility Noted on Shares of: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Engelwood Daily
07/16/16 02:44 PMBrainstorm Cell Therapeutics (BCLI) Stock Plummets Ahead of ALS Trial Results - TheStreet.com
07/15/16 01:22 PMBrainstorm to unveil results from mid-stage NurOwn study in ALS on Monday; shares up big today
07/15/16 01:22 PMWatch Out For BCLI, RARE's Phase 3 Trial Hits Goal, JUNO Opens Wallet
07/14/16 02:50 PMBrainstorm Cell Therapeutics (BCLI) Sets Date to Announce Top-Line NurOwn Phase 2 Data in ALS Patients - StreetInsider.com
07/14/16 02:30 PMBrainStorm to Announce Top Line Results from the U.S. Phase 2 Study of NurOwn in Patients with Amyotrophic Lateral Sclerosis (ALS) on Monday, July 18 - [PR Newswire] - HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 14, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, ...
07/14/16 11:41 AMEye on Stock Volatility for: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Engelwood Daily
07/13/16 02:47 PMBrainstorm Cell Therapeutics (BCLI) Updated Price Targets - FTSE News
07/13/16 02:47 PMBrainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Shorts Decreased by 9.6% After Short Covering - Consumer Eagle
07/11/16 02:46 PMShares Dipping Lower in Session: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Telanagana Press
07/11/16 02:46 PMShares Dipping Lower in Session: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Telanagana Press
07/05/16 02:45 PMBroker Outlook For The Week Ahead Brainstorm Cell Therapeutics (BCLI) - Fiscal Standard
06/30/16 02:57 PMRecently Issued Stock Ratings For Brainstorm Cell Therapeutics (BCLI) - Fiscal Standard
06/25/16 02:45 PMBrainstorm Cell Therapeutics Inc Stock Is Crashing Now. What To Expect? - Press Telegraph
06/24/16 03:11 PMBRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statement -
06/22/16 08:01 AMBRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/22/16 07:34 AMNew Broker Ratings For Brainstorm Cell Therapeutics (BCLI) - FTSE News
06/04/16 11:16 AMAnalysts Offer Insights on Healthcare Companies: Brainstorm Cell Therapeutics (NASDAQ: BCLI), Align Technology ... - Markets.co
06/03/16 11:19 AMBrainstorm Cell Therapeutics: Caution Ahead Of ALS Phase II Data
06/01/16 11:17 AMBroker Watchlist: Brainstorm Cell Therapeutics (BCLI) - Share Trading News - Broker Watchlist: Brainstorm Cell Therapeutics (BCLI)Share Trading NewsIts subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn ...
05/27/16 05:41 PMAnalysts Set 1-Year Price Target Of $7.5 On Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Stock - RealistInvestor.com - Analysts Set 1-Year Price Target Of $7.5 On Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) StockRealistInvestor.comSell-side analysts reveal their outlook on Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) stock. As of 2016-05-26, the stock has ABR of 1. This methodology prompts shareholders to invest in stock if it has a rating of 1. The ABR was known considering ...and more »
05/25/16 05:24 PMBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Closes At $2.18 - Stocks Daily - Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Closes At $2.18Stocks DailyThe technical analysis of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) stock highlights the stock is $-0.09 points away -3.96% from its 50-day MA of $2.29. It is $-0.30 or -11.84% away $2.50, the 200-day Moving Average (MA) of stock. Yesterday, the ...
05/23/16 10:22 AMBrainstorm Cell Therapeutics (BCLI) Broker Price Targets For The Coming Week - Share Trading News - Brainstorm Cell Therapeutics (BCLI) Broker Price Targets For The Coming WeekShare Trading NewsBrainstorm Cell Therapeutics has a 50 day moving average of 2.32 and a 200 day moving average of 2.51. The stock's market capitalization is 41.23M, it has a 52-week low of 1.90 and a 52-week high of 4.02. The share price of the company (BCLI) was down ...
05/21/16 08:49 AMRevenue Update on Brainstorm Cell Therapeutics Inc(NASDAQ:BCLI) - Trade Calls - Revenue Update on Brainstorm Cell Therapeutics Inc(NASDAQ:BCLI)Trade CallsBrainstorm Cell Therapeutics Inc(NASDAQ:BCLI) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 10, 2016. Earnings per share were $-0.10. Analysts had estimated an EPS of $-0.25. Brainstorm ...
05/17/16 10:30 AMBCLI: Preparing for Multi-dose Phase 2 Trial of NurOwn™ in ALS; Data From Single-dose ALS Trial in the U.S. in mid-2016… -
05/14/16 03:59 AMBrainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Basic Consolidated EPS At $-0.4612 - RealistInvestor.com - Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Basic Consolidated EPS At $-0.4612RealistInvestor.comThe yearly basic consolidated EPS for Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) for the period ended 2015-12-31 was $-0.4612. For the quarter ended 2015-12-31 the basic consolidated EPS was $-0.4612. Earnings per share is the portion of the ...Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Sellers Covered 14.09% of Their ShortsFranklin Independentall 2 news articles »
05/10/16 12:32 PMBRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition -
05/09/16 04:09 AMNext Weeks Broker Price Targets For Brainstorm Cell Therapeutics (BCLI) - Share Trading News - Next Weeks Broker Price Targets For Brainstorm Cell Therapeutics (BCLI)Share Trading NewsBrainstorm Cell Therapeutics has a 50 day moving average of 2.45 and a 200 day moving average of 2.55. The stock's market capitalization is 40.14M, it has a 52-week low of 1.90 and a 52-week high of 4.02. The share price of the company (BCLI) was down ...
04/29/16 05:49 PMBrainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Short Interest Decreased By 16.93% - B.O.D.Y Confidential - Brainstorm Cell Therapeutics Incorporated (NASDAQ:BCLI) Short Interest Decreased By 16.93%B.O.D.Y ConfidentialThe short interest to Brainstorm Cell Therapeutics Incorporated's float is 2.63%. The stock is down 5.83% or $0.14 after the news, hitting $2.26 per share. About 56,738 shares traded hands. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has declined ...

Social

About BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics logoBrainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BCLI
  • CUSIP:
Key Metrics:
  • Previous Close: $2.39
  • 50 Day Moving Average: $2.50
  • 200 Day Moving Average: $2.42
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $44.77M
  • Beta: 1.82
  • Current Year EPS Consensus Estimate: $-0.58 EPS
  • Next Year EPS Consensus Estimate: $-0.98 EPS
Additional Links:
BrainStorm Cell Therapeutics (NASDAQ:BCLI) Chart for Sunday, July, 24, 2016